Kornimate/medical-research-clean huggingface dataset:
direct comparison of svone obtained refraction to subjective manifest refraction

Conditions: Refractive Errors

Summary: the purpose of the study is to compare the final glasses prescription based on refraction obtained with svone device to the final prescription obtained via subjective manifest refraction.

uncorrected refractive error is the leading cause of vision impairment and the second leading cause of blindness worldwide, affecting 1 in 90 individuals (1). in the us population approximately 14 million individuals aged 12 years or older have visual impairment (defined as distance visual acuity of 20/50 or worse), of which more than 11 million individuals (2) could have their vision improved to 20/40 or better with refractive correction. uncorrected refractive error impacts all aspects of life, including, but not limited to, loss of employment opportunities, inability to care for family, and inability to receive an education. svone is smartphone-based autorefractor, powered by wavefront aberrometry, due to its portability and accuracy it presents as an effective and accessible method of detecting refractive error and dispensing spectacles for better vision (3). in this study, for each patient, a single clinician will determine final prescription through manifest refraction, while a different clinician will determine final prescription using svone exam protocol. sphere, cylinder and axis will be converted to power vectors and compared by linear regression analysis.

Eligibility criteria:
inclusion criteria: * subjects must be 12 (under 18 with parental consent) years of age and older up to 65 years of age. * no known ocular pathology from previous clinical exams that may limit best corrected visual acuity. exclusion criteria: * refractive error greater than +/- 14.00 diopters, or astigmatism greater than -7.00 diopters. * known ocular (corneal, lenticular, vitreal, or retinal) pathology that may limit bcva. * best corrected visual acuity with spectacles of 20/25 or worse. * any previous surgical or laser procedures that may limit bcva * 11 years of age and younger
a study to evaluate efficacy and tolerance of caelyx in patients with epithelial ovarian cancer. (study p04072)(completed)

Conditions: Ovarian Neoplasms

Summary: the aim of this study is to evaluate efficacy and tolerability, and number of positive response to treatment with caelyx (50 mg/m\^2), administered as monotherapy once per 4 weeks to patients with metastatic epithelial ovarian cancer, resistant to previous platinum therapy.


Eligibility criteria:
inclusion criteria: * subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent and/or parent or legal guardian must have signed a written informed consent. * women must be greater than or equal to 18 years of age, of any race. * women of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active) must be using an acceptable method of birth control (e.g., hormonal contraceptive, medically prescribed iud, condom in combination with spermicide) or be surgically sterilized (e.g., hysterectomy or tubal ligation). * morphology (cytology or histology) confirmed diagnosis of epithelial ovarian cancer. * patients with 1 or more measurable and/or evaluable tumors, according to the results of ct, mrt scans or x-ray, etc. * patients, including those after primary surgical treatment, who had previously received platinum chemotherapy and in whom second-line therapy is indicated. * karnofsky performance status above 60%. * left ventricular ejection fraction above 50% (according to the results of echocardiography). * adequate bone marrow function as indicated by: * platelets \>100x10\^9/l * haemoglobin \> 9 g/dl * absolute neutrophil count \>1.5x10\^9/l * adequate renal function as indicated by: * serum creatinine \< 1.5 х uln * adequate liver function as indicated by: * bilirubin level and ast or alt activity \< 2 х uln (with the exception of cases related to primary disease). exclusion criteria: * women who are pregnant or nursing. * subjects who have not observed the designated washout periods for any of the prohibited medications. * subjects who have used any investigational product within 30 days prior to enrollment. * medical history indicating serious concomitant diseases, such as congestive heart failure of ii nyha class or higher, insulin-dependent diabetes mellitus, clinically significant liver disease, mental disorders. * non-controlled bacterial, viral or fungal infections. * conditions and reasons (medical, social and psychological) that might prevent adequate follow-up of patients. * any other active primary tumor under treatment (except basal or squamous cell carcinoma or in situ cervix carcinoma). * patient has symptomatic metastasis to brain.
prt for adolescents with high functioning autism

Conditions: Autism; Autism Spectrum Disorder High-Functioning; Developmental Disability; Child Development; Behavior, Child; Behavior, Social

Summary: the purpose of this study is to identify improvement in behavioral and social function and changes in the brain following pivotal response treatment (prt) for adolescents in highly verbal adolescents with autism spectrum disorder (asd).


Eligibility criteria:
inclusion criteria: * clinical diagnosis of autism spectrum disorder, higher functioning/low support needs * intelligence quotient (iq): participants with a full scale iq \> 80 on the wechsler abbreviated scale of intelligence (wasi-ii) * right-handed * no metal in their body/unremovable metal on their body (i.e., braces) * first language is english * must live in the san francisco bay area * able and willing to receive intervention weekly for 9 weeks * adolescent is interested in improving their social skills * mri compatibility: no major contraindication for mri. * diagnosis of asd using ados-2 and adi-r. * no evidence of a genetic, metabolic, or infectious etiology for their autism. * primary diagnosis of asd * no evidence of significant difficulty during pregnancy, labor, delivery, or immediate neonatal period. * stable treatment (e.g., aba), speech therapy, school placement, psychotropic medication(s) or biomedical intervention(s) for at least 1 month prior to baseline measurements with no anticipated changes during study participation. * score of at least 50% or below on at least 4 out of the 9 social target areas in the slo (administered during pre-measures) * no evidence of significant difficulty during pregnancy, labor, delivery, or immediate neonatal period. exclusion criteria: * history of claustrophobia, previous head injury, serious neurological or medical illness, birth weight less than 4 lb. and/or gestational age \< 34 weeks * left-handed * braces or any metal in their body

Keywords: autism autism spectrum disorder prt pivotal response treatment autism intervention social skills adolescents
impact of omega-3 fatty acids on lactate

Conditions: Gastric Surgery

Summary: pre- and intra-operative nutritional support in patient undergoing major surgery results in decreased morbidity and mortality. studies investigating the role of omega-3 fatty acids in these patients are increasing. some are focused on perfusion at the cellular level. this study was undertaken to address the effect of postoperative administration of omega-3 fatty acids on cellular hypoperfusion associated with major gastric surgery.


Eligibility criteria:
inclusion criteria: * patients undergoing major gastric cancer surgery exclusion criteria: * none

Keywords: omega-3 fatty acids lactate surgery gastric cancer address the effect of postoperative administration of omega-3 fatty acids on cellular hypoperfusion associated with major gastric surgery.
the effect of dexmedetomidine in coracoid approach brachial plexus block

Conditions: Injury of Upper Limb

Summary: dexmedetomidine is an α-2 adrenoreceptor agonist and has been extensively used through intravenous infusion，in order to improved the quality of block in regional anesthesia. in this prospective, randomized study, the authors focus on the effect of dexmedetomidine mixed with ropivacaine in coracoid approach brachial plexus block.


Eligibility criteria:
inclusion criteria: 1. american society of anesthesiologists (asa) physical status i or ii; 2. aged 18-60 years; 3. the elbow, forearm, wrist or hand surgery exclusion criteria: 1. history of allergy to local anesthetics; 2. coagulation dysfunction, neuromuscular disease or local infection; 3. the operation time is longer than the local anesthetics effective time.

Keywords: dexmedetomidine coracoid brachial plexus block
bia versus physician adjustment in acute kidney injury patients requiring renal replacement therapy

Conditions: Intradialytic Hypotension; Cardiac Event; Renal Insufficiency; Hospital Length of Stay

Summary: this study was designed to compare the efficacy of bia and physician adjustment to prevent intradialytic hypotension in patients with acute kidney injury who received renal replacement therapy. the investigators randomized 9 patients with acute kidney injury and volume overloaded who underwent acute hemodialysis for 45 sessions in vajira hospital between october 2017 and february 2018. in physician adjust-group (control) estimate by physical examination and fluid balance record. primary outcome was intradialytic hypotensive episode and secondary outcome was hemodialysis-related adverse events and other clinical outcome.

background volume overload and intradialytic hypotension are significant complications with increasing mortality rate in hemodialysis patients. bioelectrical impedance analysis (bia) has been used to estimate the optimum weight in chronic hemodialysis patient to prevent intradialytic hypotension.volume assessment in acute kidney injury is also of great importance , however, there are currently few methods to obtain an accurate assessment of hydration status in this scenario. this study was designed to compare the efficacy of bia and physician adjustment to prevent intradialytic hypotension in patients with acute kidney injury who received renal replacement therapy. methods the investigators randomized 9 patients with acute kidney injury and volume overloaded who underwent acute hemodialysis for 45 sessions in vajira hospital between october 2017 and february 2018. volume overload was defined by bia with value more than\>0.4. in physician adjust-group (control) estimate by physical examination and fluid balance record. primary outcome was intradialytic hypotensive episode and secondary outcome was hemodialysis-related adverse events and other clinical outcome.

Eligibility criteria:
inclusion criteria: * patients with acute kidney injury with volume overload unresponsive to medication therapy =required renal replacement therapy (rrt) exclusion criteria: patients who were pregnant * advanced malignancy * kidney transplantation * aki from toxins * currently on pacemaker * had underlying chronic kidney disease * patients with severe cardiovascular disease such as congestive heart failure, valvular regurgition

Keywords: hemodialysis bia acute kidney injury
acupuncture-like transcutaneous electrical nerve stimulation on bowel symptom and quality of life in patients with irritable bowel syndrome

Conditions: Acupuncture-like Transcutaneous Electrical Nerve Stimulation; Irritable Bowel Syndrome

Summary: to discuss the effects of improving the irritable bowel syndrome patients' quality of life and defecation after implementing acupuncture-like transcutaneous electrical nerve stimulation.

this experiment will use a clinical design that will collect cases in a local teaching hospital. the way of convenience sampling will gather from the irritable bowel syndrome patients. after a questionnaire, randomly to make invention and control groups. invention and control groups are 4 weeks and 3 weeks respectively. each time will be for 20 minutes acupuncture-like transcutaneous electrical nerve stimulation treatment. the control group will still have normal nursing. there will be 72 patients in two groups. the measured timing will be in the second, fourth, and eighth weeks after the prediction and invention.

Eligibility criteria:
inclusion criteria: 1. those who are at least 20 years old (inclusive) and are willing to sign a written informed consent after explaining the purpose of the research. 2. a patient with irritable bowel syndrome diagnosed by a doctor for at least 6 months (inclusive). 3. communicate in mandarin or hokkien. exclusion criteria: 1. those who cannot take care of themselves in daily life. 2. those who have had severe abdominal and colorectal surgery. 3. those who have been diagnosed with inflammatory bowel disease or colorectal cancer. 4. those with a history of mental illness, such as schizophrenia and obsessive- compulsive disorder. 5. women who are pregnant, breastfeeding, and less than 12 months after delivery. 6. other serious diseases, such as acute myocardial infarction, endocrine disease, decompensated cirrhosis, stroke, and end-stage renal disease, etc.

Keywords: irritable bowel syndrome acupuncture-like transcutaneous electrical nervestimulation quality of life
behavioral abnormalities in dysphonic children

Conditions: Dysphonia

Summary: we will assess dysphonic children as regard presence of behavioral abnormalities and then receive voice therapy


Eligibility criteria:
inclusion criteria : * dysphonic children age 6-12 years exclusion criteria: * age less than 6 years and more than 12 years, * hearing impaired, * neurological abnormalities.
biweekly gemcitabine and docetaxel as first line therapy for advanced non-small cell lung cancer (nsclc) patients

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: there is little information of eastern cooperative oncology group (ecog) performance status (ps) 2 patients analyzed in the clinical trials. the rate of patients recruited into treatment chemotherapy as 1st line in advanced nsclc clinical trials is less than 20 percent. this low rate makes the investigators think about the possibility of a bias selection, due to the existence of this exclusion criteria that do not permit to include patients with deteriorated performance status. in these types of patients, the toxicity is an important issue to decide the therapeutic strategy. gemcitabine and docetaxel combination is very interesting because they have a different toxicity profile. this combination has demonstrated activity in several types of tumours, as breast cancer, sarcoma and lung cancer. the strategy performed in this study is biweekly combination of gemcitabine and docetaxel; activity and dose intensity will be the same, but toxicity will be significantly low.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of advanced nsclc. * stage iii with pleural effusion and stage iv. * patients with ecog ps 2. * patients must have at least one measurable lesion, no previously irradiated. * life expectancy of at least 12 weeks. * adequate organ function according to the following criteria: * bone marrow: anc =\> 2.0x10(9)cells/l; platelet count =\> 100x10(9)cells/l; hemoglobin =\> 10 g/dl. * liver function: bilirubin \<= 1.5 x uln; alkaline phosphatase \<= 5 x uln; ast and alt \<= 1.5 x uln. * renal function:serum creatinine \<= 2mg/dl. exclusion criteria: * prior systemic chemotherapy for advanced disease. * prior radiotherapy for nsclc. * patients with symptomatic brain metastases. * no measurable bone metastases or malignant pleural effusion as only measurable lesion. * history of prior malignancies, except curatively treated in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least five years. * history of hypersensitivity reaction study drugs. * pregnant or lactating women (women of childbearing potential must use adequate contraception). * concurrent treatment with other experimental drugs. * current peripheral neuropathy nci grade 2. * participation in clinical trials within 30 days of study entry. * major surgery, open biopsy or traumatic lesion 28 days before to study start.

Keywords: carcinoma, small cell lung neoplasms docetaxel gemcitabine ecog 2
internet-based cognitive behavioural treatment for chronic back pain

Conditions: Back Pain Lower Back Chronic

Summary: the aim of this study was to investigate whether an internet-based cognitive behavioural intervention would have an effect on the symptoms of chronic back pain.

all participants were screened in a live, structured interview before inclusion. it´s a experimental design with a treatment and a control group measured before and after a treatment period.

Eligibility criteria:
inclusion criteria: * age between 18-65 years * access to the internet * having been in contact with a physician * back pain of chronic nature * in current employment or on short-term sick leave(not longer than 6 months) exclusion criteria: * wheelchair user * surgical treatment planned * history of cardiovascular treatment * severe depression

Keywords: chronic back pain internet based treatment pain management programme cognitive behavioural therapy minimal therapist contact
interest of auriculotherapy in prophylaxis of migraine and headache in patients with migraines

Conditions: Headache, Migraine

Summary: the aim of the study is to show that auriculotherapy decreases the number of days with painful episodes of migraine and headache after 3 months of treatment

prospective, multicenter, controlled and randomized study. at the inclusion: * initial assessment of migraine and headache attacks of the last 3 months with the migraine/headache/treatment diary; * quality of life assessment (midas questionnaire). patients are randomized in 2 groups (distribution 2/3 aur+, 1/3 aur-): * aur+: experimental group "auriculotherapy". patients benefit from 3 sessions of auriculotherapy at one month intervals. * aur-: control group. patients do not benefit from auriculotherapy. after 3 months, a visit of algology is carried out : * final assessment of migraine and headache attacks of the last 3 months with the migraine/headache/treatment diary; * quality of life assessment (midas questionnaire).

Eligibility criteria:
inclusion criteria: * woman; * aged from 18 to 80; * benefiting from social security scheme or legal successor; * having given their non-opposition to the study; · * diagnosis of chronical migraine for more than 6 months; * without background treatment or with stable background therapy for more than 1 month; * presenting a calendar of migraines and headaches mentioning the number of days with pain, intensity of pain and treatments for at least 3 months. non inclusion criteria: * man; * patient with less than 6 painful episodes in 3 months; * history or actual mental health disorder; * dependence on opioids or tranquillizers; * secondary headaches; * incapacitated to keep a diary of the migraines / headaches / treatments; * contraindications for the use of auriculotherapy (scheduled magnetic resonance imaging examination, declared pregnancy, breastfeeding, artificial heart valves, haemophilia, effective anticoagulation treatment); * having received auriculotherapy treatment in the indication of the study in the last 12 months before inclusion; * scheduled to start a new drug or non-drug therapy which could interfere with the study (antidepressant, opioids, anticonvulsant psychological therapy, physiotherapy, deep brain stimulation, etc..); * modification of background treatment during the month before inclusion. exclusion criteria * allergy or infection of the auricle * pregnancy

Keywords: auriculotherapy
early rhbnp on myocardial remodeling and reperfusion in patients with stemi

Conditions: ST Segment Elevated Myocardial Infarction

Summary: the study intends to evaluate the efficacy of early rhbnp on myocardial remodeling and reperfusion in patients with st-segment elevation myocardial infarction after percutaneous coronary intervention

as prospectively observational study，it brings anterior acute myocardial infarct patients from 2018 jan. to 2019 jan, whose predefined time between symptom onset and percutaneous is not more than 12 hours. the door-to-balloon time, present to balloon time and first medical contact-to-balloon time will be documented. ecg in fmc and 90min after pci also will be record. patients assigned to the rhbnp group will receive intravenous rhbnp before pci，and the variety of heart rate and blood pressure will be record. routinely evaluation of corrected timi frame counting（ctfc）, timi myocardial perfusion frame counting and timi myocardial perfusion grade(tmpg).blood tests including bnp, ck-mb and crp are measured at admission and6, 12, 24, 48 hours after pci. both cardiovascular magnetic imaging and echocardiography will be applied in day 30 and 12 months. the composite endpoint is incidence of all-cause mortality, reinfarct, stroke and target vessel revascularization at hospitalization and follow-up. principally patients are prevented from any drug affecting microcirculation (gpiib/iia receptor agonist, vascular dilation drug, etc.), otherwise it is necessary, which should be documented.

Eligibility criteria:
patients are eligible for enrollment if they are suspected as anterior myocardial infarct (anterior myocardial infarct is defined as persistent chest pain for 30 mins at least, with st-segment elevation of at least 0.2 mv in two or more contiguous precordial leads) within 12 hours after onsets of symptom, and no contraindication for rhbnp. the coronary angiography (cag) proves left anterior descending (lad) as culprit vessel, which was totally or nearly occlusion with timi 0-1 grade and resulted in timi 3 grade after pci. exclusive criteria: 1. killips grade iii-iv. 2. unstable hemodynamic; with a-v block or atrial fibrillation; 3. contraindication of magnetic resonance, such as history of metal, icd or paceman implant; 4. history of myocardial infarct; 5. pregnancy or breeding; 6. combined with other serious diseases: severe renal dysfunction (creatinine clearance\<30ml/min;), liver failure, neutropenia, thrombocytopenia, acute pancreatitis； 7. life expectancy≤12 months

Keywords: st segment elevated myocardial infarction rhbnp cardiac magnetic resonance microvascular disease ventricular remodeling